ANDA 203166

ANDA APPROVAL

Nexgen Pharma, Inc.
1835 East Cheyenne Road
Colorado Springs, CO 80905-2868
Attention: Deepak Thassu, MBA, Ph.D.
Vice President of Research and Development and Regulatory

Dear Sir:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on November 18, 2011, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Nabumetone Tablets USP, 500 mg, 750 mg, and 1,000 mg.[1]

Reference is also made to the complete response letter issued by this office on May 22, 2019, and to any amendments thereafter.

Reference is also made to the ANDA Suitability Petition (FDA-2007-P-0495/CP1) submitted on July 10, 2007, under Section 505(j)(2)(C) of the FD&C Act and approved on March 18, 2010. This petition requested the Agency make a determination as to whether an application for Nabumetone Tablets USP, 1,000 mg, was suitable for submission as an ANDA. This determination was necessary because the 1,000 mg strength proposed in your ANDA differs from the strengths of the reference listed drug product (RLD), Relafen Tablets, 500 mg and 750 mg, of GlaxoSmithKline.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the ANDA is **approved**, effective on the date of this letter. We have determined your Nabumetone Tablets USP, 500 mg and 750 mg, to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD) Relafen Tablets, 500 mg and 750 mg, of GlaxoSmithKline. We have also determined that Nabumetone Tablets USP, 1,000 mg, can be expected to have the same therapeutic effect as that of the listed drug product upon which the agency relied as the basis of safety and effectiveness.

Under section 506A of the FD&C Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Please note that if FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

REPORTING REQUIREMENTS

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98 and at section 506I of the FD&C Act. The Agency should be advised of any change in the marketing status of this drug or if this drug will not be available for sale after approval. In particular, under section 506I(b) of the FD&C Act, you are required to notify the Agency in writing within 180 days from the date of this letter if this drug will not be available for sale within 180 days from the date of approval. As part of such written notification, you must include (1) the identity of the drug by established name and proprietary name (if any); (2) the ANDA number; (3) the strength of the drug; (4) the date on which the drug will be available for sale, if known; and (5) the reason for not marketing the drug after approval.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling materials prior to publication or dissemination. Please note that these submissions are voluntary. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert (PI), Medication Guide, and patient PI (as applicable) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

You must also submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at: http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at: http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of

Prescription Drug Promotion (OPDP), see:
http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

ANNUAL FACILITY FEES

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions[2] with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1st of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the *Federal Register* notice announcing facility fee amounts.

All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at: http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at: https://www.fda.gov/media/71211/download.

The SPL will be accessible via publicly available labeling repositories.

Sincerely yours,

{See appended electronic signature page}

For Vincent Sansone, Pharm.D.
Deputy Director
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research

[1] We note that the RLD upon which you have based this ANDA, GlaxoSmithKline's Relafen Tablets, 500 mg and 750 mg, are no longer being marketed in the United States and are currently listed in the discontinued section of FDA's *Approved Drug Products with Therapeutic Equivalence Evaluations* (the "Orange Book"). The Agency has determined that GlaxoSmithKline's Relafen Tablets, 500 mg and 750 mg, were not withdrawn from sale for reasons of safety or effectiveness. FDA published this determination in the *Federal Register* (73 FR 12453; March 7, 2008). This determination allows the Agency to approve ANDAs for the discontinued drug products.

[2] Some of these provisions were amended by the Generic Drug User Fee Amendments of 2017 (GDUFA II) (Public Law 115-52, Title III).

Sarah Kurtz

Digitally signed by Sarah Kurtz
Date: 8/30/2019 06:55:50PM
GUID: 54078879000a1b9e15dd31ed6f0343ca